Ani Pharmaceuticals (ANIP) Short term Debt (2012 - 2026)

Ani Pharmaceuticals has disclosed Short term Debt across 12 years of filings, most recently posting $21.3 million for Q2 2026.

• In Q2 2026, Short term Debt rose 61.39% year-over-year to $21.3 million; the TTM figure through Jun 2026 stood at $21.3 million (up 61.39% YoY), while the FY2025 annual figure was $17.3 million, up 88.27% from the prior year.
• Short term Debt came in at $21.3 million for Q2 2026 at Ani Pharmaceuticals, up from $19.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $25.0 million in Q2 2023 to a low of $850000.0 in Q1 2022.
• Average Short term Debt over 5 years is $11.3 million, with a median of $11.7 million recorded in 2023.
• Year-over-year, Short term Debt surged 2844.12% in 2023 and slumped 96.6% in 2024.
• Over 5 years, Short term Debt stood at $850000.0 in 2022, then soared by 1343.06% to $12.3 million in 2023, then retreated by 25.22% to $9.2 million in 2024, then surged by 88.27% to $17.3 million in 2025, then advanced by 23.52% to $21.3 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $21.3 million in Q2 2026, $19.3 million in Q1 2026, and $17.3 million in Q4 2025.